Medical Advocates
Lopinavir/Ritonavir (Kaletra/Aluvia)
 
Journal Citations: Resistance

General Reports                               
Cross Resistance      







 
KLS Main Page KLS Journal Main Page Home
Last Update: June 19, 2008
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

Resistance: General Reports
 
 
Enzymatic and Structural Analysis of the I47A Mutation Contributing to the Reduced Susceptibility
to HIV Protease Inhibitor Lopinavir.
 Grantz Saskova K, Kozisek M, et al 
Protein Sci. 2008 Jun 17.
Abstract
 
Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance.
 de Mendoza C, Garrido C, Corral A, et al  
AIDS. 2008 Jan 11;22(2):311-3.
 Abstract
 
Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance.
 de Mendoza C, Garrido C, Corral A  
AIDS. 2008 Jan 11;22(2):311-3.
 Abstract
 
Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir
in patients with HIV
Ma Q, Brazeau D, Zingman BS, et al  
Pharmacogenomics. 2007 Mar;8(3):227-235.
Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
 The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of
lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease
inhibitor-experienced patients.
Maillard A, Chapplain JM, Tribut O, et al 
J Clin Virol. 2007 Jan 3;
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
 Ability of different lopinavir genotypic inhibitory quotients to predict 48-week
virological response in highly treatment-experienced HIV-infected patients
receiving lopinavir/ritonavir.
Gianotti N, Galli L, Danise A, et al 
J Med Virol. 2006 Oct 24;78(12):1537-1541
Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
 Prevalence of the HIV-1 protease mutation I47A in clinical practice and association
with lopinavir resistance.
 de Mendoza C, Valer L, Bacheler L, et al 
AIDS. 2006 Apr 24;20(7):1071-4.
 Abstract
 
Relationship between Adherence and the Development of Resistance in
Antiretroviral-Naive, HIV-1-Infected Patients Receiving Lopinavir/Ritonavir or
Nelfinavir.
King MS, Brun SC, Kempf DJ.
 Infect Dis. 2005 Jun 15;191(12):2046-52.
Abstract
 
Selection of resistance in protease inhibitor-experienced, human
immunodeficiency virus type 1infected subjects failing lopinavir- and
ritonavir-based therapy: mutation patterns and baseline correlates.
Mo H , King MS, King K, Molla A, et al  
J Virol. 2005 Mar;79(6):3329-38.
 Abstract
 
Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-
based regimen.
Friend J, Parkin N, Liegle T, et al
AIDS. 18(14):1965-1966, September 24, 2004.
 Letter

Safety, Efficacy and Development of Resistance under the New Protease Inhibitor
Lopinavir/Ritonavir: 48-Week Results.
Voigt E, Wasmuth JC, Vogel M, et al 
Infection. 2004 Apr;32(2):82-8.
 Abstract
 
Incidence of Resistance in a Double-Blind Study Comparing Lopinavir/Ritonavir
Plus Stavudine and Lamivudine to Nelfinavir plus Stavudine and Lamivudine.
Kempf DJ, King MS, Bernstein B, et al
J Infect Dis. 2004 Jan 1;189(1):51-60
 Abstract

Characterization of resistant HIV variants generated by in vitro passage with
lopinavir/ritonavir.
Mo H, Lu L, Dekhtyar T, Stewart KD, et al
Antiviral Res. 2003 Aug;59(3):173-80
 Abstract

FULL-TEXT  ARTICLE
 The Irresistible Dale Kempf Discusses Kaletra Resistance
 Hawes J
Thoughtleaders 2003 Apr
Paper
 
Accumulation of lopinavir resistance-associated mutations over 3 years follow-up of
patients on highly active antiretroviral therapy: implication in salvage therapy.
Tsuchiya K, Matsuoka S, Hachiya A, et al
AIDS. 15(9):1183-1184, June 15, 2001.
Letter

Cross Resistance
 
  New patterns of HIV-1 resistance during HAART.
Fumero E, Podzamczer D. 
Clin Microbiol Infect. 2003 Nov;9(11):1077-84.
 Abstract

FULL-TEXT ARTICLE
 Improving lopinavir genotype algorithm through phenotype correlations:
novel mutation patterns and amprenavir cross-resistance.
Parkin NT, Chappey C, Petropoulos CJ
AIDS 2003 May 2;17(7):955-61
 Paper

FULL-TEXT ARTICLE
Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir,
and atazanavir in a panel of clinical samples.
Schnell, Tanja; Schmidt, Barbara; Moschik, et al
AIDS. 17(8):1258-1261, May 23, 2003.
 Paper

Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced
replication capacity.
Prado JG, Wrin T, Beauchaine J, et al.
AIDS 2002 May 3;16(7):1009-17
 Abstract

Genotypic and phenotypic cross-resistance patterns to lopinavir and
amprenavir in protease inhibitor-experienced patients with HIV viremia.
 Paulsen D, Liao Q, Fusco G, St Clair M, et al.
AIDS Res Hum Retroviruses 2002 Sep 20;18(14):1011-9
 Abstract

  

KLS Main Page KLS Journal Main Page Home

Lopinavir/Ritonavir
Journal Papers/Abstracts/Commentaries: Resistance